Developing first-in-class therapeutics
Disease/Injury manipulates the ICE to enable its progression; reverting ICE changes makes it possible to develop treatment for every disease.
MicroQuin focuses in-house efforts on Cancer, while progressing Anti-Virals and Neuro with the support of collaborators.
Focusing on transforming cancer treatment for solid tumors
MicroQuin's orally available lead small molecule, SMQ-2174, exclusively induces rapid cancer death irrespective of the cancer type.